Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and raises the price target from $17 to $19.
HC Wainwright & Co. Maintains Buy Rating for RAPT Therapeutics: Here’s What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of RAPT Therapeutics (NASDAQ:RAPT) and raise its price target from $50.00 to $53.00.
Shares of RAPT Therapeutics are trading up 14.98% over the last 24 hours, at $28.01 per share.
